Biomedical Engineering Reference
In-Depth Information
expression of both pro- and anti-inflammatory genes in vascular cells and tissues.
An unexpected finding was that neointima formation in a perivascular collar-
induced injury model was reduced by the systemic administration of the dsRNA
analog Poly(I:C) in a TLR3-dependent manner. Furthermore, genetic deletion of
TLR3 dramatically enhanced the development of elastic lamina damage after collar-
induced injury. Deficiency of TLR3 accelerated the onset of atherosclerosis in
hypercholesterolemic ApoE−/− mice. These data indicate a protective role for TLR
signaling in the vessel wall.
Important Advances in Cardiovascular Therapeutics
The most important advances in cardiovascular therapeutics are:
1. Advances in cardiovascular surgery
2. Cell therapy: transplantation of cells for repair of myocardial damage
3. Gene therapy: to promote angiogenesis for repair of heart
4. Statin drugs to reduce hypercholesterolemia
5. Platelet blocker drugs to prevent blood clots
6. Nitric oxide therapeutics
7. Stents, particularly drug-eluting stents, for preventing restenosis of coronary
arteries
8. Advances in cardiac catheterization
9. Cardiovascular imaging for interventional cardiology and cardiac diagnosis
10. Advances in cardiac monitoring and pacemakers
References
Arab S, Gramolini AO, Ping P, et al. Cardiovascular Proteomics: Tools to Develop Novel
Biomarkers and Potential Applications. J Am Coll Cardiol 2006;48:1733-41.
Asakura M, Kitakaze M. Cardioprotection in the clinical setting-lessons from J-WIND studies.
Cardiovasc Drugs Ther 2010;24:289-95.
Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, et al. Statins and dilated cardiomyopathy: do
we have enough data? Expert Opin Investig Drugs 2011;20:315-23.
Bookstein JJ, Fellmeth B, Roberts A, et al. Pulsed-spray pharmacomechanical thrombolysis:
preliminary clinical results. AJR Am J Roentgenol 1989;152:1097-1100.
Cadenas S, Aragonés J, Landázuri MO. Mitochondrial reprogramming through cardiac oxygen
sensors in ischaemic heart disease. Cardiovasc Res 2010;88:219-28.
Carreira RS, Monteiro P, Gon Alves LM, Providência LA. Carvedilol: just another Beta-blocker
or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006;6:257-66.
Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol
2008;103:203-15.
Cole JE, Navin TJ, Cross AJ, et al. Unexpected protective role for Toll-like receptor 3 in the arterial
wall. PNAS 2011 January 10; doi: 10.1073/pnas.1018515108.
Search WWH ::
Custom Search